Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Shares
-
Shares outstanding
-
124,058,172
-
Total 13F shares
-
39,458,483
-
Share change
-
-4,628,175
-
Total reported value
-
$35,390,510
-
Put/Call ratio
-
245%
-
Price per share
-
$0.90
-
Number of holders
-
39
-
Value change
-
-$10,271,988
-
Number of buys
-
17
-
Number of sells
-
31
Institutional Holders of ADC Therapeutics SA - Common Shares (ADCT) as of Q3 2023
As of 30 Sep 2023,
ADC Therapeutics SA - Common Shares (ADCT) was held by
39 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
39,458,483 shares.
The largest 10 holders included
Redmile Group, LLC, Prosight Management, LP, Sio Capital Management, LLC, CITADEL ADVISORS LLC, MILLENNIUM MANAGEMENT LLC, Frazier Life Sciences Management, L.P., BANK OF AMERICA CORP /DE/, Affinity Asset Advisors, LLC, AlphaCentric Advisors LLC, and GOLDMAN SACHS GROUP INC.
This page lists
40
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.